A Long-Term Survival Of Small Cell Lung Cancer Developed Diffuse Large B-Cell Lymphoma

10.5580/2cf6 ◽  
2013 ◽  
Vol 14 (1) ◽  
Keyword(s):  
Lung Cancer ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Term Survival ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Long-Term Survival and Gradual Recovery of B Cells in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel)

2021 ◽  
Vol 27 (3) ◽  
pp. S404-S405
Author(s):  
Caron A. Jacobson ◽  
Frederick L. Locke ◽  
Armin Ghobadi ◽  
David B. Miklos ◽  
Lazaros J. Lekakis ◽  
...  
Keyword(s):  
B Cells ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Term Survival ◽  
Long Term Survival ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals ESTIMATION OF LONG‐TERM SURVIVAL WITH TAFASITAMAB + LENALIDOMIDE (LEN) IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)

2021 ◽  
Vol 39 (S2) ◽  
Author(s):  
G Salles ◽  
B Goswami ◽  
V Bagnardi ◽  
D Dey ◽  
M Winderlich ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Term Survival ◽  
Long Term Survival ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Non-Relapse Mortality Exceeds Relapse Mortality Six Years After Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 3325-3325
Author(s):  
Brian T. Hill ◽  
Lisa Rybicki ◽  
Brian J. Bolwell ◽  
Stephen Smith ◽  
Robert Dean ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
B Cell ◽  
Partial Remission ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Term Survival ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Abstract Abstract 3325 Poster Board III-213 For patients with diffuse large B-cell lymphoma (DLBCL) who failed to achieve complete remission (CR) or who relapsed after obtaining CR with initial treatment, salvage therapy has historically resulted in poor long-term survival. The PARMA trial identified high dose chemotherapy followed by autologous stem cell transplantation (ASCT) as a superior treatment modality compared to standard chemotherapy. As originally reported in 1995, the 5-year event-free-survival (EFS) was 46% in patients undergoing ASCT, compared to 12% in patients receiving chemotherapy alone. Subsequent to the widespread adoption of ASCT, it has been noted that patients who have undergone autologous transplantation for relapsed or refractory DLBCL may be at increased risk of mortality well beyond 5 year point which has generally been an accepted surrogate for long-term survival. To assess long-term outcomes of these patients, we retrospectively analyzed data from 309 consecutive patients who received ASCT for DLBCL at the Cleveland Clinic from January 1994 through December 2006. Inclusion criteria were age ≥ 18 years, diagnosis of DLCBL, and history of a single autologous stem cell transplant. The median age of these patients was 51 years (range 19-72) and 61.2% were male. The median time from diagnosis of DLBCL to transplant was 14.7 months (range 2.1-372.3). 99.0% of patients received peripheral blood stem cells and 98.4% received a preparative regimen with busulfan/cyclophosphamide/VP16. As shown in the accompanying figure, non-relapse mortality (NRM) becomes the major cause of death approximately 6 years after ASCT. The most common causes of NRM during the study period were pulmonary toxicity (31%), infection (17%), cardiac toxicity (15%) and secondary malignancy (15%). In multivariate analysis, the strongest predictor of relapse mortality was disease status at transplant: patients who were in second complete or partial remission had a higher risk of relapse mortality than those in first complete or partial remission (hazard ratio [HR] 3.70, P<0.001), as did those who were relapsed or refractory (HR 4.85, P<0.001) Significant risk factors for NRM were older age (HR 1.43, P=0.017 per 10 year increase), prior chemotherapy (HR 1.31, P=0.030 per 1 regimen increase), and poor performance status at the time of transplant (HR 4.66, P=0.010 for KPS 50-80 relative to KPS 100). In conclusion, we describe the longest reported follow-up of a large cohort of DLBCL patients uniformly-treated with ASCT. We have found that although relapse is initially the more likely cause of death, after six years, NRM exceeds relapse mortality. As more patients with DLBCL survive ASCT, these findings emphasize the need for active surveillance for causes of morbidity and mortality other than relapsed lymphoma. Disclosures No relevant conflicts of interest to declare.

scholarly journals Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma

2019 ◽  
Vol 25 (12) ◽  
pp. 2522-2526
Author(s):  
Jessica El-Asmar ◽  
Lisa Rybicki ◽  
Brian J. Bolwell ◽  
Mohamed A. Kharfan-Dabaja ◽  
Robert Dean ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Term Survival ◽  
Large B Cell Lymphoma ◽  
Autologous Hematopoietic Cell Transplantation ◽  
Large B Cell

scholarly journals Dynamic prediction of long-term survival in patients with primary gastric diffuse large B-cell lymphoma: a SEER population-based study

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Ju-Li Lin ◽  
Jian-Xian Lin ◽  
Ping Li ◽  
Jian-Wei Xie ◽  
Jia-bin Wang ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Population Based ◽  
Dynamic Prediction ◽  
Term Survival ◽  
Population Based Study ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Factors predicting long-term survival in low-risk diffuse large B-cell lymphoma

2003 ◽  
Vol 74 (2) ◽  
pp. 94-98 ◽  
Author(s):  
Michael B. Møller ◽  
Niels T. Pedersen ◽  
Bjarne E. Christensen
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Low Risk ◽  
Term Survival ◽  
Long Term Survival ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals LONG-TERM SURVIVAL AND LOSS IN EXPECTANCY OF LIFE IN A POPULATION-BASED COHORT OF 7114 PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

2017 ◽  
Vol 35 ◽  
pp. 127-128
Author(s):  
K.E. Smedby ◽  
S. Ekberg ◽  
P. Andersson ◽  
G. Enblad ◽  
B.E. Wahlin ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Population Based ◽  
Term Survival ◽  
Long Term Survival ◽  
Large B Cell Lymphoma ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document